Equillium

EQ504, an aryl hydrocarbon receptor (AhR) modulator is our newest asset. It targets a clinically validated pathway for the treatment of skin & GI diseases with a unique, multi-modal, non-immunosuppressive MoA that is complementary to other therapeutics. bit.ly/4cVtEQZ

Announced Ph3 aGVHD data. Itolizumab did not improve CR or OR rates at Day 29, but did achieve stat sig in 2nd'ry endpoints demonstrating compelling clinical benefit in longer-term outcomes, including CR at Day 99, duration of CR and failure free survival. bit.ly/4c1qkmU

@EquilliumBio announces abstract at #SITC24. Poster will highlight data demonstrating that IL-15 & IL-21 augment NK and CD8 T cell activity and enhance proliferation & cytolytic function. Combo could be a promising treatment approach to stimulating anti-tumor immune response.

Join us on September 28 as we #WalkForAlopecia to help raise money for @NAAF_org naaf.org/walk/

Join us on October 5th for the "2024 Walk to End Lupus Now" sponsored by the San Diego chapter of the Lupus Foundation of America. You can mkae a difference! support.lupus.org/site/TR/WTELN/…

It's conference season again! $EQ presenting on Tuesday at @HCWCO Investor Conference to provide an update on itolizumab and Ono Pharmaceutical partnership. equilliumbio.com/investors/even…

$EQ presenting today at Wells Fargo and providing an update on itolizumab and Ono Pharmaceutical partnership. equilliumbio.com/investors/even…

Please join us in welcoming our newest Clinical Operations Team member, Annie Huynh. She joins us as a Clinical Trial Manger and will be supporting the EQUATOR program for aGVHD. In her spare time, Annie enjoys Pilates, cycling and catching halibut under the Coronado Bridge.

$EQ Announces Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease. Triggers Ono Pharmaceutical's 90-Day exercise period. bit.ly/3Ytsya6

$EQ Announces Second Quarter 2024 Estimated Cash and Investments Balance of approximately $33.3 million. An increase of approximately $1.0 million compared to the amount at the end of Q1. equilliumbio.com/investors/pres…

Thanks @NAAF_org Looking forward to a great event with Dr. Brett King. #alopecia

UPCOMING #WEBINAR – Novel developments in treating #AlopeciaAreata: What is Type 2 inflammation and why is it important? Wed., July 17 at 7pm ET/4pm PT Learn more and register: us02web.zoom.us/webinar/regist…

You can impact #AlopeciaAreata awareness when you join the #WalkForAlopecia this September. Lace up your shoes and hit the pavement to raise awareness! Naaf.org/walk

EQ Announces Positive Data in Ph 2 Alopecia Areata (AA) Study · 20% all subjects completing 24wks treatment achieved SALT ≤ 20 · 29% completed subjects with moderate - severe disease achieved SALT ≤ 20 · Drug well tolerated in subjects with no SAEs equilliumbio.com/investors/pres…

In recognition of International Celiac Disease Awareness Day, @CeliacDotOrg supports schools and students nationwide for their annual Celiac Strong Day. See how you can contribute here: celiac.org/celiacstrongda…

Great event coming from @NAAF_org at the end of June, with special guests and knowledgeable speakers to offer inspiration. Medical professionals will share valuable information and advice to better understand and manage alopecia areata. naaf.org/events/patient…

Equillium Announces Poster Presentation at #AAI2024, the Annual Meeting of @ImmunologyAAI "Surface CD6 regulates T cell adhesion and migration through direct ligand interaction and stabilization of VLA4" Full poster available here: bit.ly/3UoItTq

Great interview with $EQ CEO, Bruce Steel, in recent Biotech & Pharmaceuticals report by @wstranscript bit.ly/4b5AS2O

@EquilliumBio's lupus drug improves kidney #biomarker, teeing up opt-in decision from Ono. Find out more here: fiercebiotech.com/biotech/equlli…

EQ Management is presenting tomorrow, April 9th at @theLDMicro event in New York